Rectal Diclofenac administration for prevention of post-Endoscopic Retrograde Cholangio-Pancreatography (ERCP) acute pancreatitis. Randomized prospective study

被引:23
作者
Geraci, G. [1 ]
Palumbo, V. D. [1 ]
D'Orazio, B. [1 ]
Maffongelli, A. [1 ]
Fazzotta, S. [1 ]
Lo Monte, A., I [1 ]
机构
[1] Univ Teaching Hosp Paolo Giaccone Palermo, Sect Gen & Thorac Surg, Palermo, Italy
来源
CLINICA TERAPEUTICA | 2019年 / 170卷 / 05期
关键词
Diclofenac; ERCP; pancreatitis; complication; prevention; COMPLICATIONS;
D O I
10.7417/CT.2019.2156
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Post-Endoscopic Retrograde Cholangio-Pancreatography pancreatitis (PEP) is a relevant (1-4%) complication of biliopancreatic operative endoscopy. Rectal nonsteroidal anti-inflammatory drugs (specifically, 100 mg of diclofenac) have shown promising prophylactic activity in PEP. The aim of our prospective study is to report whether prophylactic oral versus rectal suppository versus intramuscular diclofenac versus placebo are able to reduce the incidence and the severity of ERCP-induced pancreatitis. Materials and Methods. in this randomized, double-blinded, prospective study, 100 patients (49 male, 51 female), similar with regard to indication for ERCP, were enrolled between January 2016 and November 2017 to undergo ERCP in the Section of General and Thoracic Surgery of University Hospital of Palermo. They were randomized into five groups, respectively 20 patients with placebo by mouth; 20 patients with 50 mg diclofenac sodium enteric-coated capsules by mouth; 20 with 100 mg rectal suppository diclofenac, 20 with 75 mg/3 ml intramuscular diclofenac sodium, 20 with 75 mg/3 ml intramuscular diclofenac sodium and 20 with 75 mg/3 ml intravenous diclofenac. All drugs were administered 30 to 90 minutes before ERCP. All clinical data were collected one day before and 2, 12 and 24 hour after ERCP. Results. data were prospectively collected and to demonstrate the preventive effect of rectal diclofenac on PEP, a two-by-two table and chi-square test with Yates correction were used: the incidence of PEP was significantly lower (p < 0.001) in the rectal diclofenac group respect to other groups and, in the same way. the incidence of post-ERCP pain was significantly lower in the rectal diclofenac group than in the other groups (p = 0.001) and patients discharge was consequently earlier (p < 0.01). Conclusions. 100 mg dose rectal diclofenac administered 30-60 minutes before ERCP can effectively prevent PEP.
引用
收藏
页码:E332 / E336
页数:5
相关论文
共 50 条
  • [21] Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in the Indomethacin Era - A Prospective Study
    Perdigoto, David N.
    Gomes, Dario
    Almeida, Nuno
    Mendes, Sofia
    Alves, Ana Rita
    Camacho, Ernestina
    Tome, Luis
    GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2019, 26 (03) : 176 - 183
  • [22] A randomized trial comparing the efficacy of single-dose and double-dose administration of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis
    Lai, Jian-Han
    Hung, Chien-Yuan
    Chu, Cheng-Hsin
    Chen, Chih-Jen
    Lin, Hsiang-Hung
    Lin, Han-Jung
    Lin, Ching-Chung
    MEDICINE, 2019, 98 (20)
  • [23] Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis
    Hiroaki Sakai
    Naoto Iwai
    Junichi Sakagami
    Takashi Okuda
    Tomoya Ohara
    Chie Hattori
    Masashi Taniguchi
    Kohei Oka
    Tasuku Hara
    Toshifumi Tsuji
    Toshiyuki Komaki
    Keizo Kagawa
    Osamu Dohi
    Hiroaki Yasuda
    Hideyuki Konishi
    Yoshito Itoh
    Surgical Endoscopy, 2023, 37 : 2698 - 2705
  • [24] Rectal versus intramuscular diclofenac in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: experience of a Greek tertiary referral center
    Kalantzis, Ioannis
    Poulou, Androniki
    Papatheodorou, Athanasios
    Gkoumas, Konstantinos
    ANNALS OF GASTROENTEROLOGY, 2020, 33 (04): : 412 - 417
  • [25] Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis
    Sakai, Hiroaki
    Iwai, Naoto
    Sakagami, Junichi
    Okuda, Takashi
    Ohara, Tomoya
    Hattori, Chie
    Taniguchi, Masashi
    Oka, Kohei
    Hara, Tasuku
    Tsuji, Toshifumi
    Komaki, Toshiyuki
    Kagawa, Keizo
    Dohi, Osamu
    Yasuda, Hiroaki
    Konishi, Hideyuki
    Itoh, Yoshito
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2023, 37 (04): : 2698 - 2705
  • [26] Nafamostat Mesilate for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis A Prospective, Randomized, Double-Blind, Controlled Trial
    Yoo, Kyo-Sang
    Huh, Kyung Rim
    Kim, Yu Jin
    Kim, Kyoung Oh
    Park, Cheol Hee
    Hahn, Taeho
    Park, Sang Hoon
    Kim, Jong Hyeok
    Park, Choong Kee
    Kwon, Young-Jun
    Lehman, Glen A.
    PANCREAS, 2011, 40 (02) : 181 - 186
  • [27] Can Iodixanol Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis? A Prospective, Randomized, Controlled Trial
    Ogura, Takeshi
    Imoto, Akira
    Okuda, Atsushi
    Fukunishi, Shinya
    Higuchi, Kazuhide
    DIGESTIVE DISEASES, 2019, 37 (03) : 255 - 261
  • [28] Is the Combination of Rectal Diclofenac and Intravenous Ringer Lactate Superior to Individual Therapy for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis A Prospective, Open-Label, Single-Center Randomized Trial
    Thanage, Ravi
    Jain, Shubham
    Chandnani, Sanjay
    Udgirkar, Suhas
    Nair, Sujit
    Debnath, Prasanta
    Jain, Samit
    Rathi, Pravin
    PANCREAS, 2021, 50 (08) : 1236 - 1242
  • [29] Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial
    Ueki, Toshiharu
    Otani, Keisuke
    Kawamoto, Kenichiro
    Shimizu, Aiko
    Fujimura, Naruhito
    Sakaguchi, Seigo
    Matsui, Toshiyuki
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 161 - 167
  • [30] Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial
    Toshiharu Ueki
    Keisuke Otani
    Kenichiro Kawamoto
    Aiko Shimizu
    Naruhito Fujimura
    Seigo Sakaguchi
    Toshiyuki Matsui
    Journal of Gastroenterology, 2007, 42 : 161 - 167